Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C53H72N2O12.2C6H5O3S |
| Molecular Weight | 1243.479 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-]S(=O)(=O)C1=CC=CC=C1.[O-]S(=O)(=O)C2=CC=CC=C2.COC3=C(OC)C=C(C[C@@H]4C5=CC(OC)=C(OC)C=C5CC[N@+]4(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]6(C)CCC7=CC(OC)=C(OC)C=C7[C@H]6CC8=CC(OC)=C(OC)C=C8)C=C3
InChI
InChIKey=XXZSQOVSEBAPGS-DONVQRBFSA-L
InChI=1S/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2/t42-,43-,54-,55-;;/m1../s1
DescriptionCurator's Comment: description was created based on several sources, including www.ncbi.nlm.nih.gov/pubmed/9349062
Curator's Comment: description was created based on several sources, including www.ncbi.nlm.nih.gov/pubmed/9349062
Cisatracurium is a cis-cis isomer of atracurium and five time as potent as atracurium. The drug is approved by FDA and marketed under the name Nimbex. It is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation due to its antagonistic properties toward nicotinic acetylcholine receptors.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2362997 |
54.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | NIMBEX Approved UseCisatracurium besylate injection is an intermediate-onset/intermediate-duration neuromuscular blocking agent indicated for inpatients and outpatients as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation in the ICU. Launch Date1995 |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
22 min |
0.1 mg/kg 1 times / day steady-state, intravenous dose: 0.1 mg/kg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
CISATRACURIUM unknown | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Prolonged weakness after cisatracurium infusion: a case report. | 1998 Jul |
|
| Effects of pretreatment with cisatracurium, rocuronium, and d-tubocurarine on succinylcholine-induced fasciculations and myalgia: a comparison with placebo. | 1999 Dec |
|
| Severe anaphylactic reaction to cisatracurium. | 1999 Feb |
|
| [Precurarization of succinylcholine with cisatracurium: the influence of the precurarization interval]. | 2002 Sep |
|
| Acute motor axonal polyneuropathy after a cisatracurium infusion and concomitant corticosteroid therapy. | 2004 Feb |
|
| Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. | 2005 Oct |
|
| Distinct pharmacologic properties of neuromuscular blocking agents on human neuronal nicotinic acetylcholine receptors: a possible explanation for the train-of-four fade. | 2006 Sep |
|
| Acute coronary syndrome in cisatracurium-induced anaphylactic shock: Kounis syndrome. | 2008 Dec |
|
| [Type IV anaphylactic reaction and ST-elevation acute coronary syndrome due to coronary vasospasm secondary to administration of cisatracurium]. | 2008 Jun-Jul |
Patents
Sample Use Guides
The recommended initial doses is 0.2 mg/kg, however it should be individualized. A dose of 0.03 mg/kg is recommended for maintenance of neuromuscular block during prolonged surgical procedures.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Y78PS7MEDE
Created by
admin on Fri Dec 15 15:46:47 GMT 2023 , Edited by admin on Fri Dec 15 15:46:47 GMT 2023
|
PRIMARY | |||
|
62886
Created by
admin on Fri Dec 15 15:46:47 GMT 2023 , Edited by admin on Fri Dec 15 15:46:47 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
